TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer –– Investigational New Drug (IND) application for TNG456, a ...

Q4 2024 Earnings Call Transcript March 5, 2025 Ocugen, Inc. reports earnings inline with expectations. Reported EPS is $-0.05 ...

Ocugen ( OCGN -3.41%) Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET ...

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis. TEL AVIV, Israel, (GLOBE NEWSWIRE) -- C ...

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

Scholar Rock Holding Corporation. ( NASDAQ: SRRK) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial ...

Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...

A new drug application is anticipated for 2029. The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has been cleared by the FDA ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic CAR T-cell therapy, paving the way for a phase 1 trial in lupus and other autoimmune diseases.

Kadimastem and iTolerance believe that the completion of the pre-IND meeting is a significant milestone toward the clinical ...